The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors

• Nikola Geskovski,
• Nadica Matevska-Geshkovska,
• Simona Dimchevska Sazdovska,
• Marija Glavas Dodov,
• Kristina Mladenovska and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2021, 12, 375–401, doi:10.3762/bjnano.12.31

• leukemia cell population, Mandal and co-workers developed mesoporous silica nanoparticles decorated with an anti-B220 antibody intended for B220+LSC targeting [53]. The daunorubicin-loaded targeted nanoparticles demonstrated selective efficacy against B220+/Mac1− cells, relative to B220− AML LSCs. In

Rational design of block copolymer self-assemblies in photodynamic therapy

• Maxime Demazeau,
• Laure Gibot,
• Anne-Françoise Mingotaud,
• Patricia Vicendo,
• Clément Roux and
• Barbara Lonetti

Beilstein J. Nanotechnol. 2020, 11, 180–212, doi:10.3762/bjnano.11.15

Bombesin receptor-targeted liposomes for enhanced delivery to lung cancer cells

• Mohammad J. Akbar,
• Pâmela C. Lukasewicz Ferreira,
• Melania Giorgetti,
• Leanne Stokes and
• Christopher J. Morris

Beilstein J. Nanotechnol. 2019, 10, 2553–2562, doi:10.3762/bjnano.10.246

• , leading to accumulation of nanocarriers in the tumour. A diversity of targeting ligands has been explored, including antibodies, proteins, peptides and aptamers. Targeted nanoparticles such as HER2-targeted MM-302 [14], transferrin receptor-targeted CALAA-01 [15], and prostate-specific membrane antigen

Polydopamine-coated Au nanorods for targeted fluorescent cell imaging and photothermal therapy

• Boris N. Khlebtsov,
• Andrey M. Burov,
• Timofey E. Pylaev and
• Nikolai G. Khlebtsov

Beilstein J. Nanotechnol. 2019, 10, 794–803, doi:10.3762/bjnano.10.79

• demonstrated insignificant cell toxicity (Figure 2A,B) for particle concentrations up to 2.5 × 1010 mL−1. At very high concentrations and after 48 h of incubation time the cell viability decreased to 83% and 76% only for AuNRs-PDA-R123-folate. We attributed this effect to a better uptake of targeted

• nanoparticles compared with PEG-coated particles. HeLa (F+) and HEK 293 (F−) cells were incubated with AuNR-PDA-R123-folate and AuNR-PDA-R123-PEG at a nanoparticle dose of 1010 mL−1 for 2 h. Fluorescent images of randomly selected cells under 488 nm light excitation were obtained using a Leica DM 2500

Targeting strategies for improving the efficacy of nanomedicine in oncology

• Gonzalo Villaverde and
• Alejandro Baeza

Beilstein J. Nanotechnol. 2019, 10, 168–181, doi:10.3762/bjnano.10.16

• targeting strategies. In this review, recent advances in the development of targeted nanoparticles will be described with the aim to present the current state of the art of this technology and its huge potential in the oncological field. Keywords: antitumoral therapy; nanomedicine; smart nanocarriers

• ; targeted nanoparticles; Introduction Nanotechnology has become a powerful weapon in the search of novel strategies for addressing unmet clinical challenges, from the treatment of complex diseases as cancer or neurological disorders, to the early diagnosis of these pathologies that could allow for

• more than 72 h. Non-targeted nanoparticles were rapidly cleared. Interestingly, MSN decorated with the same type of PEG but without MABG at the end failed to be accumulated in the tumoral area, but they showed slight accumulation in the liver of the animal, probably due to the increase in the

Antitumor magnetic hyperthermia induced by RGD-functionalized Fe₃O₄ nanoparticles, in an experimental model of colorectal liver metastases

• Oihane K. Arriortua,
• Eneko Garaio,
• Borja Herrero de la Parte,
• Maite Insausti,
• Luis Lezama,
• Fernando Plazaola,
• Jose Angel García,
• Jesús M. Aizpurua,
• Maialen Sagartzazu,
• Mireia Irazola,
• Nestor Etxebarria,
• Ignacio García-Alonso,
• Alberto Saiz-López and
• José Javier Echevarria-Uraga

Beilstein J. Nanotechnol. 2016, 7, 1532–1542, doi:10.3762/bjnano.7.147

• . Nanotherapy based on targeted nanoparticles could become an attractive alternative to conventional oncologic treatments as it allows a local heating in tumoral surroundings without damage to healthy tissue. RGD-peptide-conjugated MNPs have been designed to specifically target αVβ3 receptor-expressing cancer

Magnetic nanoparticles for biomedical NMR-based diagnostics

• Huilin Shao,
• Tae-Jong Yoon,
• Monty Liong,
• Ralph Weissleder and
• Hakho Lee

Beilstein J. Nanotechnol. 2010, 1, 142–154, doi:10.3762/bjnano.1.17

• biomolecules and cells based on magnetic resonance effects. This detection platform, termed diagnostic magnetic resonance (DMR), exploits magnetic nanoparticles as proximity sensors, which modulate the spin–spin relaxation time of water molecules surrounding molecularly-targeted nanoparticles. By developing